Evidence map›Paper›PMID 38137507›Full record

ReviewBiomedicines2023

Unraveling Down Syndrome: From Genetic Anomaly to Artificial Intelligence-Enhanced Diagnosis.

Aabid Mustafa Koul, Faisel Ahmad, Abida Bhat, Qurat-Ul Aein, Ajaz Ahmad, Aijaz Ahmad Reshi, Rauf-Ur-Rashid Kaul

Open access · goldAbstract readReview
In one paragraph

Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Aabid Mustafa KoulDepartment of Immunology and Molecular Medicine, Sher-i-Kashmir Institute of Medical Sciences, Srinagar 190006, India.ORCID 0000-0001-9127-9155
Faisel AhmadDepartment of Zoology, Central University of Kashmir, Ganderbal, Srinagar 190004, India.
Abida BhatAdvanced Centre for Human Genetics, Sher-i-Kashmir Institute of Medical Sciences, Srinagar 190011, India.
Qurat-Ul AeinDepartment of Human Genetics, Guru Nanak Dev University, Amritsar 143005, Punjab, India.
Ajaz AhmadDepartments of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Aijaz Ahmad ReshiDepartment of Computer Science, College of Computer Science and Engineering, Taibah University, Madinah 42353, Saudi Arabia.ORCID 0000-0002-0795-2835
Rauf-Ur-Rashid KaulDepartment of Community Medicine, Sher-i-Kashmir Institute of Medical Sciences, Srinagar 190006, India.
Sher-i-Kashmir Institute of Medical Sciences · INCentral University of Kashmir · INGuru Nanak Dev University · INKing Saud University · SATaibah University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Down syndrome arises from chromosomal non-disjunction during gametogenesis, resulting in an additional chromosome. This anomaly presents with intellectual impairment, growth limitations, and distinct facial features. Positive correlation exists between maternal age, particularly in advanced cases, and the global annual incidence is over 200,000 cases. Early interventions, including first and second-trimester screenings, have improved DS diagnosis and care. The manifestations of Down syndrome result from complex interactions between genetic factors linked to various health concerns. To explore recent advancements in Down syndrome research, we focus on the integration of artificial intelligence (AI) and machine learning (ML) technologies for improved diagnosis and management. Recent developments leverage AI and ML algorithms to detect subtle Down syndrome indicators across various data sources, including biological markers, facial traits, and medical images. These technologies offer potential enhancements in accuracy, particularly in cases complicated by cognitive impairments. Integration of AI and ML in Down syndrome diagnosis signifies a significant advancement in medical science. These tools hold promise for early detection, personalized treatment, and a deeper comprehension of the complex interplay between genetics and environmental factors. This review provides a comprehensive overview of neurodevelopmental and cognitive profiles, comorbidities, diagnosis, and management within the Down syndrome context. The utilization of AI and ML represents a transformative step toward enhancing early identification and tailored interventions for individuals with Down syndrome, ultimately improving their quality of life.

Indexed as

artificial intelligencecognitive impairmentcomorbiditydiagnosisDown syndromeintellectual disabilitymachine learningmanagementneurodevelopmentneurological disorders

Identifiers

PMID38137507
PMCPMC10741860
OpenAlexW4389626724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.